COVID-19: Information on ASPIRA LABS Operations

Click to Learn More
  • Home
  • Recent News and Upcoming Events

Recent News and Upcoming Events

Recent News


  • Vermillion to Report First Quarter 2020 Financial Results on May 14

    For a pdf of the press release click here AUSTIN, Texas, April 30, 2020 – Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will report financial results for the first quarter ended March 31, 2020, on Thursday, May 14, 2020, after the market close, followed by…

  • Vermillion Inc. Announces ASPiRA LABS Now Credentialed as Florida State Medicaid Provider

    Fourth largest Medicaid population in the U.S. For a pdf of this press release click here AUSTIN, Texas, April 14, 2020 –Vermillion, Inc. (NASDAQ: VRML) today announced its wholly owned subsidiary, ASPiRA LABS, is now credentialed with Florida’s State Medicaid program for an estimated additional 3.6 million credentialed Medicaid lives. Florida has the fourth largest state…

  • Vermillion Announces Cigna Preferred Contract Coverage for OVA1, OVERA and Genetics Testing

    For a pdf of this press release click here AUSTIN, Texas, March 27, 2020 – Vermillion, Inc. (NASDAQ: VRML), a bioinformatics-based women’s health company focused on gynecologic disease, announced yesterday that its wholly owned subsidiary, ASPiRA Labs, has signed a national preferred agreement with Cigna. This contract includes OVA1, (Multivariate Index Assay, MIA) our ACOG endorsed…

  • Vermillion Reports Fourth Quarter 2019 Financial Results

    For a pdf of this press release please click here Click Here for Earnings Supplement AUSTIN, Texas — March 26, 2020 — Vermillion, Inc. (Nasdaq: VRML), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the fourth quarter and year ended December 31, 2019. “We are very pleased with…

  • ASPIRA LABS COVID-19 Update: Laboratory remains open

    To Our Valued Customers, As we continue to monitor COVID-19 developments we wanted to update you on ASPIRA LABS processes during this time.  When making the choice to order either OVA1®plus or ASPIRA GENETIXSM we will continue to provide you with the best ASPIRA service for your patients. Please find details below: Our laboratory and…

Investor Relations